In our 2019 cohort, mortality risk was significantly influenced only by age (HR 1.02, p = 0.0007), When comparing the pooled HV-infected patients from the two cohorts it seems that after the 5 years DAA therapy program it was less inflammation among the 2019 infected group (CRP p < 0.0001, Ferritin p = 0.0001), higher prevalence of coronary artery disease (p < 0.0001), but a lower prevalence of peripheric artery disease (p = 0.009), stroke (p < 0.0001) and heart valve calcification (p = 0.035). The gene discussed is CRP; the disease is stroke disorder.